Dr. Beatriz Jardim

Dr. Beatriz Jardim is one of Brazil's foremost medical oncologists, practicing at Hospital Sírio-Libanês in São Paulo — consistently ranked among Latin America's top private hospitals for oncology care. Over more than two decades, she has built a reputation for combining rigorous evidence-based medicine with a deeply patient-centred approach, ensuring that each treatment plan is tailored to the individual's molecular tumour profile, overall health status, and personal goals.

Her clinical focus centres on breast and thoracic malignancies, where she has contributed substantially to advancing the adoption of targeted therapies and immuno-oncology protocols across Brazil. Dr. Jardim is a frequent participant in multidisciplinary tumour boards at Hospital Sírio-Libanês, collaborating with surgical oncologists, radiation oncologists, pathologists, and palliative care specialists to deliver integrated cancer care.

Dr. Jardim is recognised for her active engagement with international oncology societies, including ASCO and ESMO, and regularly updates her practice in line with the latest global clinical trial data. She has been involved in several multicentre clinical trials exploring novel combinations of checkpoint inhibitors and targeted agents in solid tumours.

Beyond her clinical duties, Dr. Jardim is committed to medical education, mentoring oncology residents and fellows at the hospital's academic programme. She believes that high-quality cancer care requires both scientific excellence and compassionate communication, particularly when guiding patients and families through complex treatment decisions.

Dr. Jardim completed her medical degree at the Universidade de São Paulo (USP), one of Brazil's most prestigious research universities, graduating with distinction. She subsequently undertook her Internal Medicine residency at Hospital das Clínicas FMUSP, followed by a dedicated fellowship in Medical Oncology at Hospital Sírio-Libanês, where she was exposed to a high-volume oncology caseload covering virtually every major tumour type.

She earned her PhD in Oncology from USP, with her doctoral research focusing on predictive biomarkers for response to chemotherapy in breast cancer patients. To expand her expertise in immuno-oncology, Dr. Jardim completed a research fellowship at a leading European cancer centre, gaining hands-on experience with next-generation immunotherapy protocols. She holds board certification from the Brazilian Society of Clinical Oncology (SBOC) and maintains active membership with ASCO and ESMO, attending their annual congresses to remain at the forefront of evolving standards of care.

Dr. Jardim's primary expertise lies in medical oncology, with deep specialisation in breast oncology and thoracic oncology. She is experienced in designing and overseeing chemotherapy protocols, targeted therapy regimens (including HER2-directed agents, EGFR inhibitors, and CDK4/6 inhibitors), and immunotherapy programmes using PD-1/PD-L1 checkpoint inhibitors.

She routinely manages patients with early-stage breast cancer requiring neoadjuvant or adjuvant systemic therapy, as well as those with metastatic disease requiring complex, sequentially managed treatment plans. In thoracic oncology, she treats non-small cell lung cancer (NSCLC) with both targeted agents and immunotherapy, guided by molecular profiling including EGFR, ALK, and ROS1 mutation analysis.

Dr. Jardim also has significant experience in gastrointestinal oncology and ovarian cancer, and is proficient at interpreting comprehensive genomic profiling reports to guide precision medicine decisions. She routinely enrolls eligible patients into clinical trials, giving them access to investigational therapies not yet widely available.

Dr. Jardim's research career has focused primarily on translational oncology — bridging laboratory discoveries with clinical practice improvements. Her doctoral work on predictive biomarkers in breast cancer was published in peer-reviewed oncology journals and contributed to refining patient selection criteria for specific chemotherapy regimens used in Brazilian clinical practice.

She has co-authored papers on immuno-oncology response rates in Brazilian patient cohorts and has presented findings at ASCO and SBOC annual meetings. Her ongoing research interests include exploring the interaction between tumour microenvironment characteristics and immunotherapy efficacy in Latin American patient populations, which may differ in important ways from those in North American or European clinical trial cohorts.

Dr. Jardim conducts consultations in both Portuguese and English, making her accessible to international patients seeking oncology second opinions or treatment at Hospital Sírio-Libanês. She is experienced in coordinating care for patients travelling to São Paulo from other Latin American countries, the United States, and Europe.

For international patients, Dr. Jardim's team at Hospital Sírio-Libanês can arrange comprehensive oncology consultations that include tumour board review, molecular profiling of tissue samples, and a structured treatment plan delivered in both Portuguese and English. Video consultations are available for pre-visit reviews of existing pathology reports and imaging, allowing patients to receive a preliminary assessment before committing to travel. The hospital's international patient services department provides logistical support for accommodation, translation, and insurance coordination.

Dr. Jardim holds board certification from the Brazilian Society of Clinical Oncology (SBOC) and is recognised as a specialist in Medical Oncology by the Brazilian Federal Council of Medicine (CFM). She has been acknowledged within Hospital Sírio-Libanês's academic programme for her contributions to clinical education and mentorship. Her participation in international multicentre clinical trials reflects the recognition of her expertise by global oncology research networks. She is a full member of ASCO and ESMO, having been invited to serve as a faculty discussant at regional oncology symposia.